This may explain the nonsignificant difference in GAPP <3, despite a numerical trend.
← all excerpts
Who can safely discontinue lifelong follow-up among patients with sporadic pheochromocytoma and paraganglioma?
2
—
—
The sentences
After excluding patients with bilateral PCC or multiple PGL (Table S5 ), we found significant differences in age and PCC size, along with a marginally significant difference in the proportion of patients with a PASS <4 or a GAPP score <3 between the recurrence and non‐recurrence groups.